Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 105, doi. 10.3233/KCA-229003
- By:
- Publication type:
- Article
Works matching IS 24684562 AND DT 2022 AND VI 6 AND IP 2
Results: 8
1
2
The Current Status of Kidney Cancer Urine Markers – A Systematic Review.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 137, doi. 10.3233/KCA-220005
- By:
- Publication type:
- Article
3
Clinical Trials Corner: Adding up in Adjuvant.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 143, doi. 10.3233/KCA-229002
- By:
- Publication type:
- Article
4
Immune Gene Signature Expression Differs between African American and Caucasian Patients with Renal Cell Carcinoma.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 109, doi. 10.3233/KCA-220003
- By:
- Publication type:
- Article
5
What We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 95, doi. 10.3233/KCA-220004
- By:
- Publication type:
- Article
6
Geographical Differences in Kidney Cancer Outcomes of Patients Treated with Immunotherapy: A Systematic Review.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 129, doi. 10.3233/KCA-210124
- By:
- Publication type:
- Article
7
A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 115, doi. 10.3233/KCA-210012
- By:
- Publication type:
- Article
8
Hereditary Renal Cell Carcinoma.
- Published in:
- Kidney Cancer (2468-4562), 2022, v. 6, n. 2, p. 83, doi. 10.3233/KCA-210008
- By:
- Publication type:
- Article